Ernexa Therapeutics Inc.

Ernexsa Therapeutics Inc. announced the appointment of Robert J. Spiegel, M.D. to its Board of Directors, effective immediately. Dr. Spiegel will serve until his successor is elected or until his earlier departure. His compensation will follow the Company's Board of Directors Compensation Plan. There are no undisclosed arrangements or family relationships between Dr. Spiegel and the Company or its officers and directors.

Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors. Mr. Polinsky, a seasoned biotechnology founder and public company CFO, brings over 25 years of experience in oncology, capital markets, M&A, and corporate governance. This appointment strengthens the company's leadership team as it prepares for the Investigational New Drug (IND) submission for its lead program, ERNA-101, in Q3 2026, and the initiation of its first Phase 1 clinical study in Q4 2026.

Ernexa Therapeutics Inc. reported a net loss of $4.0 million for the three months ended June 30, 2026, and $9.5 million for the six months, which included a $2.0 million goodwill impairment charge. The company ended the period with $5.0 million in cash and an accumulated deficit of $255.2 million. Management noted a going concern risk but expects to cover shortfalls through its At-the-Market (ATM) program, having raised $3.7 million post-quarter end.

Ernexa Therapeutics announced compelling new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition. The study successfully reproduced earlier findings, demonstrating complete tumor clearance and durable long-term survival in 67% of treated animals, with no complete responses in monotherapy or control groups. This validation strengthens confidence as the company plans its IND submission in Q3 2026 and anticipates a first-in-human Phase 1 clinical trial in Q4 2026.

Ernexa Therapeutics announced progress for its lead cell therapy candidate, ERNA-101, designed to treat advanced ovarian cancer. The company plans to submit an Investigational New Drug (IND) application in Q3 2026, with the first-in-human Phase 1 study anticipated to begin in Q4 2026. CEO Sanjeev Luther highlighted ERNA-101's potential to transform immunologically 'cold' tumors and discussed encouraging preclinical data, including complete tumor clearance and 100% long-term survival in ovarian cancer models.

Ernexa Therapeutics Inc. announced the release of an updated investor presentation on July 2, 2026. This new presentation supersedes the one previously posted on February 26, 2026. The company stated that the updated presentation will be accessible on its investor relations website starting July 3, 2026.

Ernexa Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on July 1, 2027, where 53.13% of outstanding shares were represented. Stockholders elected five directors to the Board, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan.

Ernexa Therapeutics Inc. announced the resignation of Sandra Gurrola, its Senior Vice President of Finance, effective July 3, 2026. The company stated that her departure was not due to any disagreement regarding its operations, policies, or practices. Ms. Gurrola has agreed to provide part-time transition assistance until the filing of the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa Therapeutics has begun a search for a successor and plans to utilize external support for finance, accounting, and reporting matters in the interim.

Ernexa Therapeutics has launched its new "CEO Corner" platform, featuring President and CEO Sanjeev Luther. This platform is designed to offer stakeholders deeper insights into the company's developments, scientific progress, strategic priorities, and its mission to advance innovative cell therapies. The initiative aims to enhance communication beyond traditional announcements, focusing on improving accessibility and affordability of treatments for advanced cancer and autoimmune diseases. The inaugural video highlights Ernexa's mission, scientific strategy, and commitment to differentiated cell therapies.

Ernexa Therapeutics announced significant progress for its lead oncology candidate, ERNA-101, with manufacturing process development completed and GMP production underway. The company plans to submit an Investigational New Drug (IND) application in Q3 2026 and initiate a first-in-human Phase 1 clinical study in Q4 2026 for platinum-resistant ovarian cancer. Preclinical data demonstrated compelling anti-tumor activity, especially in combination with PD-1 blockade. Ernexa also stated it has sufficient resources from a recent $10.5 million financing to support its near-term development strategy and anticipated milestones.